Michael Sofia
2021
In 2021, Michael Sofia earned a total compensation of $1.6M as Chief Scientific Officer at Arbutus Biopharma Corp, a 29% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $207,966 |
|---|---|
| Option Awards | $938,944 |
| Salary | $452,100 |
| Other | $10,150 |
| Total | $1,609,160 |
Sofia received $938.9K in option awards, accounting for 58% of the total pay in 2021.
Sofia also received $208K in non-equity incentive plan, $452.1K in salary and $10.2K in other compensation.
Rankings
In 2021, Michael Sofia's compensation ranked 6,953rd out of 12,406 executives tracked by ExecPay. In other words, Sofia earned more than 44.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,953 out of 12,406 | 44th |
Division Manufacturing | 3,041 out of 5,492 | 45th |
Major group Chemicals And Allied Products | 1,346 out of 2,368 | 43rd |
Industry group Drugs | 1,201 out of 2,089 | 43rd |
Industry Pharmaceutical Preparations | 873 out of 1,536 | 43rd |
Source: SEC filing on April 11, 2022.
Sofia's colleagues
We found two more compensation records of executives who worked with Michael Sofia at Arbutus Biopharma Corp in 2021.
News
Arbutus Biopharma Corp CEO William Collier's 2023 pay jumps 28% to $3.4M
April 10, 2024
Arbutus Biopharma Corp CEO William Collier's 2022 pay slips 18% to $2.6M
April 12, 2023
Arbutus Biopharma Corp CEO William Collier's 2021 pay rises 18% to $3.2M
April 11, 2022
Arbutus Biopharma Corp CEO William Collier's 2020 pay rises 17% to $2.7M
April 8, 2021
Arbutus Biopharma Corp CEO Mark Murray's 2019 pay jumps 50% to $3.8M
April 24, 2020